Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXIS GUTIERREZ

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1700806106
CMS profile
213670
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$5,103.28

69 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,208.86 28
Food and Beverage $1,894.42 41

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $2,422.08 37
Novartis Pharmaceuticals Corporation $1,617.24 22
Merck Sharp & Dohme LLC $877.26 6
Medtronic, Inc. $150.00 1
Lilly USA, LLC $18.55 2
E.R. Squibb & Sons, L.L.C. $18.15 1

Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXIS GUTIERREZ

NPI 1700806106 · CMS profile ID 213670

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700806106?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXIS GUTIERREZ, NPI 1700806106, CMS profile ID 213670. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700806106?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALEXIS GUTIERREZ, NPI 1700806106, CMS profile ID 213670. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700806106?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALEXIS GUTIERREZ, NPI 1700806106, CMS profile ID 213670, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1700806106?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

69 matching records · $5,103.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 69 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–69 of 69.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $51.7906/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136021434 CMS
Eli Lilly and Company $15.0006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136022707 CMS
Eli Lilly and Company $118.7306/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136025499 CMS
Eli Lilly and Company $32.9606/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136025503 CMS
Eli Lilly and Company $176.4806/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135996588 CMS
Eli Lilly and Company $180.1006/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136018970 CMS
Novartis Pharmaceuticals Corporation $18.6206/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786217 CMS
Lilly USA, LLC $12.1105/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136021436 CMS
Lilly USA, LLC $6.4404/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136021234 CMS
Novartis Pharmaceuticals Corporation $171.3504/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786221 CMS
Novartis Pharmaceuticals Corporation $203.8104/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786229 CMS
Novartis Pharmaceuticals Corporation $140.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786227 CMS
Novartis Pharmaceuticals Corporation $20.0004/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786213 CMS
Novartis Pharmaceuticals Corporation $19.3303/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786211 CMS
Novartis Pharmaceuticals Corporation $15.8902/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786215 CMS
E.R. Squibb & Sons, L.L.C. $18.1501/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101754415 CMS
Medtronic, Inc. $150.0001/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119444613 CMS
Novartis Pharmaceuticals Corporation $3.9701/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786207 CMS
Novartis Pharmaceuticals Corporation $23.0001/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086786209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $842.36 27
PY2020 $409.26 10
PY2021 $766.13 23
PY2022 $733.99 32
PY2023 $2,749.66 40
PY2024 $5,103.28 69
PY2025 $3,955.90 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $437.69 2
PY2025 Principal investigator $3,008,080.95 42
PY2024 Recipient $22,894.81 2
PY2024 Principal investigator $2,665,868.71 25
PY2023 Principal investigator $1,680,328.41 17
PY2022 Principal investigator $414,931.06 10
PY2021 Principal investigator $162,066.89 175
PY2020 Recipient $52,328.45 55
PY2020 Principal investigator $28,494.47 38
PY2019 Recipient $73,884.15 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $626.99 12/24/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190310110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,953.86 12/19/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC LLC
A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184279142
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Las Palmas Medical Research Center DBA Inpatient Research Clinic
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220771255
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 12/17/2025 Non-covered Recipient Entity
Las Palmas Medical Research Center DBA Inpatient Research Clinic
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220771257
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Las Palmas Medical Research Center DBA Inpatient Research Clinic
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220771259
Principal investigator 1 Eli Lilly and Company $313.03 12/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 (SOLBINSIRAN) IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA No dispute reported 06/30/2026 1187880561
Principal investigator 1 Janssen Research & Development, LLC $10,020.00 12/15/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,589.98 12/11/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC LLC
A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184274681
Principal investigator 1 AstraZeneca Pharmaceuticals LP $110,409.00 12/03/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185539739
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,639.24 11/25/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190309960
Principal investigator 1 Janssen Research & Development, LLC $7,529.00 11/21/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197498
Principal investigator 1 Janssen Research & Development, LLC $6,147.00 10/22/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197383
Principal investigator 1 Janssen Research & Development, LLC $6,717.00 09/19/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197409
Principal investigator 1 Janssen Research & Development, LLC $10,317.00 08/25/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197308
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41,858.50 07/29/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185539741
Principal investigator 1 Amgen Inc. $3,827.19 07/28/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246642730
Principal investigator 1 Janssen Research & Development, LLC $6,001.00 07/23/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197368
Principal investigator 1 Janssen Research & Development, LLC $8,189.00 06/26/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197484
Principal investigator 1 Janssen Research & Development, LLC $6,998.00 06/20/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197349
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,450.00 06/12/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190312007
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,600.00 05/22/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190312001
Principal investigator 1 Janssen Research & Development, LLC $6,621.00 05/16/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197316
Principal investigator 1 Novartis Pharmaceuticals Corporation $111,185.35 04/28/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190311997
Principal investigator 1 Janssen Research & Development, LLC $5,651.00 04/23/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197476
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,690.43 04/16/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190310112
Recipient Eli Lilly and Company $132.59 03/27/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187871103
Recipient Eli Lilly and Company $305.10 03/20/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187873301
Principal investigator 1 Janssen Research & Development, LLC $6,029.00 03/17/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197359
Principal investigator 1 Novartis Pharmaceuticals Corporation $382,462.76 03/05/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190311987
Principal investigator 1 Eli Lilly and Company $5,916.78 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187879895
Principal investigator 1 Janssen Research & Development, LLC $8,507.00 02/24/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197417
Principal investigator 1 Novartis Pharmaceuticals Corporation $315,711.35 02/19/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190311983
Principal investigator 1 Novartis Pharmaceuticals Corporation $224,252.82 02/05/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190311993
Principal investigator 1 Novartis Pharmaceuticals Corporation $148,360.00 01/30/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190300951
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,550.00 01/28/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC, LLC
A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome No dispute reported 06/30/2026 1190310106
Principal investigator 1 Novartis Pharmaceuticals Corporation $104,650.39 01/24/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag No dispute reported 06/30/2026 1190312017
Principal investigator 1 Janssen Research & Development, LLC $5,200.00 01/22/2025 Non-covered Recipient Entity
Inpatient Rsrch Clnc Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175197323
Principal investigator 1 Eli Lilly and Company $228,769.00 01/21/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC DBA LAS PALMAS RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187882862
Principal investigator 1 Eli Lilly and Company $592.77 01/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187879201
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,844.00 01/16/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1190312005
Principal investigator 1 Novartis Pharmaceuticals Corporation $751,617.02 01/16/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312015
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 01/16/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) No dispute reported 06/30/2026 1190312019
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,271.37 01/15/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINICAL LLC
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190311991
Principal investigator 1 Eli Lilly and Company $232,582.00 01/07/2025 Non-covered Recipient Entity
INPATIENT RESEARCH CLINIC DBA LAS PALMAS RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882066